Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney

Neuropeptides

Volumn 46, Issue 2, 2012, Pages 61-70

  Reglodi, Dora ^a   Kiss, Peter ^a   Horvath, Gabriella ^a   Lubics, Andrea ^a   Laszlo, Eszter ^a   Tamas, Andrea ^a   Racz, Boglarka ^b   Szakaly, Peter ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Cisplatin; Cyclosporine A; Ischemia; Kidney; Myeloma; Oxidative stress

Indexed keywords

CISPLATIN; CYCLOSPORIN A; FRACTALKINE; GENTAMICIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PARAPROTEIN; POLYPEPTIDE; PROTEIN BCL 2; RANTES; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANTIINFLAMMATORY ACTIVITY; DIABETIC NEPHROPATHY; DRUG EFFECT; HUMAN; HYPOXIA; IMMUNOREACTIVITY; ISCHEMIA; KIDNEY; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE CELL; MEDULLA OBLONGATA; MICTURITION; MITOCHONDRIAL PERMEABILITY; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; URINARY TRACT;

ANIMALS; ANOXIA; CISPLATIN; CYCLOSPORINE; HUMANS; ISCHEMIA; KIDNEY; KIDNEY DISEASES; OXIDATIVE STRESS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; REPERFUSION; URINARY TRACT;

EID: 84858295185     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2011.05.001     Document Type: Review

References (108)

1. Arimura A., Li M., Batuman V. Potential protective action of pituitary adenylate cyclase activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 2006, 107:661-668.
2. Arimura A., Li M., Batuman V. Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38. Ann. NY Acad. Sci. 2006, 1070:1-4.
3. Arimura A., Somogyvari-Vigh A., Miyata A., Coy D.H., Kitada C. Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 1991, 129:2787-2789.
4. Arms L., Vizzard M.A. Neuropeptides in lower urinary tract function. Handb. Exp. Pharmacol. 2011, 202:395-423.
5. Armstrong B.D., Abad C., Chhith S., Cheung-Lau G., Hajji O.E., Nobuta H., Waschek J.A. Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide. Neuroscience 2008, 151:63-73.
6. Atlasz T., Babai N., Kiss P., Reglo{doubleacute}di D., Tamás A., Szabadfi K., Tóth G., Hegyi O., Lubics A., Gábriel R. Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. Gen. Comp. Endocrinol. 2007, 153:108-114.
7. Azuma Y.T., Hagi K., Shintani N., Kuwamura M., Nakajima H., Hashimoto H., Baba A., Takeuchi T. PACAP provides colonic protection against dextran sodium sulfate induced colitis. J. Cell Physiol. 2008, 216:111-119.
8. Bossowska A., Crayton R., Radziszewski P., Kmiec Z., Majewski M. Distribution and neurochemical characterization of sensory dorsal root ganglia neurons supplying porcine urinary bladder. J. Physiol. Pharmacol. 2009, 60(Suppl. 4):77-81.
9. Bourgault S., Chatenet D., Wurtz O., Doan N.D., Leprince J., Vaudry H., Fournier A., Vaudry D. Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug. Curr. Pharm Des. 2011, 17:1002-1024.
10. Braas K.M., May V., Zvara P., Nausch B., Kliment J., Dunleavy J.D., Nelson M.T., Vizzard M.A. Role for pituitary adenylate cyclase activating polypeptide in cystitis-induced plasticity of micturition reflexes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 290:R951-R962.
11. Brubel, R., Horvath, G., Reglodi, D., Lubics, A., Tamas, A., Kiss, P., Laszlo, E., Nemeth, J., Mark, L., Szakaly, P. Presence of pituitary adenylate cyclase activating polypeptide and its type I receptor in the rat kidney. Transplant. Proc., accepted for publication.
12. de Groat W.C., Yoshimura N. Changes in afferent activity after spinal cord injury. Neurourol Urodyn 2010, 29:63-76.
13. Dejda A., Jolivel V., Bourgault S., Seaborn T., Fournier A., Vaudry H., Vaudry D. Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: A better understanding towards therapeutic applications in neurodegenerative diseases. J. Mol. Neurosci. 2008, 36:26-37.
14. + thymocytes from glucocorticoid-induced apoptosis. Blood 1996, 12:5152-5161.
15. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. J. Immunol. 2000, 164:1200-1210.
16. Fahrenkrug J., Hannibal J. Pituitary adenylate cyclase activating polypeptide immunoreactivity in capsaicin-sensitive nerve fibres supplying the rat urinary tract. Neuroscience 1998, 83:1261-1272.
17. Ferencz A., Racz B., Tamas A., Reglodi D., Lubics A., Nemeth J., Nedvig K., Kalmar-Nagy K., Horvath O.P., Weber G., Roth E. Influence of PACAP on oxidative stress and tissue injury following small bowel autotransplantation. J. Mol. Neurosci. 2009, 37:168-176.
18. Ferencz A., Kiss P., Weber Gy., Helyes Zs., Shintani N., Baba A., Reglodi D. Comparison of intestinal warm ischemic injury in PACAP knock-out and wild-type mice. J. Mol. Neurosci. 2010, 42:435-442.
19. Ferencz A., Weber Gy., Helyes Zs., Hashimoto H., Baba A., Reglodi D. Presence of endogenous PACAP-38 ameliorated intestinal cold preservation tissue injury. J. Mol. Neurosci. 2010, 42:428-434.
20. Ganea D., Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit. Rev. Oral. Biol. Med. 2002, 13:229-237.
21. Gardiner S.M., Rakhit T., Kemp P.A., March J.E., Bennett T. Regional haemodynamic responses to pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in conscious rats. Br. J. Pharmacol. 1994, 111:589-597.
22. Gasz B., Racz B., Roth E., Borsiczky B., Ferencz A., Tamás A., Cserepes B., Lubics A., Gallyas F., Tath G., Lengvari I., Reglodi D. Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stress-induced apoptosis. Peptides 2006, 27:87-94.
23. Girard B.M., Wolf-Johnston A., Braas K.M., Birder L.A., May V., Vizzard M.A. PACAP-mediated ATP release from rat urothelium and regulation of PACAP/VIP and receptor mRNA in micturition pathways after cyclophosphamide (CYP)-induced cystitis. J. Mol. Neurosci. 2008, 36:310-320.
24. Girard B.M., Malley S.E., Braas K.M., May V., Vizzard M.A. PACAP/VIP and receptor characterization in micturition pathways in mice with overexpression of NGF in urothelium. J. Mol. Neurosci. 2010, 42:378-389.
25. Giunta S., Castorina A., Adorno A., Mazzone V., Carnazza M.L., D'Agata V. PACAP and VIP affect NF1 expression in rat malignant peripheral nerve sheath tumor (MPNST) cells. Neuropeptides 2010, 44:45-51.
26. Gutierrez-Canas I., Rodriguez-Henche N., Bolanos O., Carmena M.J., Prieto J.C., Juarranz M.G. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Br. J. Pharmacol. 2003, 139:1050-1058.
27. Hannibal J. Roles of PACAP-containing retinal ganglion cells in circadian timing. Int. Rev. Cytol. 2006, 251:1-39.
28. Harmar A.J., Sheward W.J., Morrison C.F., Waser B., Gugger M., Reubi J.C. Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Endocrinology 2004, 145:1203-1210.
29. Hatanaka M., Tanida M., Shintani N., Isojima Y., Kawaguchi C., Hashimoto H., Kakuda M., Haba R., Nagai K., Baba A. Lack of light-induced elevation of renal sympathetic nerve activity and plasma corticosterone levels in PACAP-deficient mice. Neurosci. Lett. 2008, 444:153-156.
30. Hautmann M., Friis U.G., Desch M., Todorov V., Castrop H., Segerer F., Otto C., Schutz G., Schweda F. Pituitary adenylate cyclase activating polypeptide stimulates renin secretion via activation of PAC1 receptors. J. Am. Soc. Nephrol. 2007, 18:1150-1156.
31. Hernandez M., Barahona M.V., Recio P., Rivera L., Benedito S., Martinez A.C., Garcia-Sacristan A., Orensanz L.M., Prieto D. Heterogeneity of neuronal and smooth miscel receptors involved in the VIP- and PACAP-induced relaxations of the pig intravesical ureter. Br. J. Pharmacol. 2004, 141:123-131.
32. Hernandez M., Barahona M.V., Recio P., Benedito S., Martinez A.C., Rivera L., Garcia-Sacristan A., Prieto D., Orensanz L.M. Neuronal and smooth muscle receptors involved in the PACAP-and VIP-induced relaxations of the pig urinary bladder neck. Br. J. Pharmacol. 2006, 149:100-109.
33. Hong X., Huang L., Song Y. Role of vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide in the vaginal wall of women with stress urinary incontinence and pelvic organ prolapse. Int. Urogynecol. J. 2008, 19:1151-1157.
34. Horvath G., Mark L., Brubel R., Szakaly P., Racz B., Kiss P., Tamas A., Helyes Z., Lubics A., Hashimoto H., Baba A., Shintani S., Furjes G., Nemeth J., Reglodi D. Mice dificient in pituitary adenylate cyclase activating polypeptide display increased sensitivity to renal oxidative stress in vitro. Neurosci. Lett. 2010, 469:70-74.
35. Horvath G., Racz B., Reglodi D., Kovacs K., Kiss P., Gallyas F., Bognar Z., Szabo A., Magyarlaki T., Laszlo E., Lubics A., Tamas A., Toth G., Szakaly P. Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia-reperfusion. J. Mol. Neurosci. 2010, 42:411-418.
36. Horvath G., Racz B., Szakaly P., Kiss P., Laszlo E., Hau L., Tamas A., Helyes Zs., Lubics A., Hashimoto H., Baba A., Reglodi D. Mice deficient in neuropeptide PACAP demonstrate increased sensitivity to in vitro kidney hypoxia. Transplant. Proc. 2010, 42:2293-2295.
37. Horvath G., Reglodi D., Opper B., Brubel R., Tamas A., Kiss P., Toth G., Csernus V., Matkovits A., Racz B. Effects of PACAP on the oxidative stress induced cell death in chicken pinealocytes is influenced by the phase of the circadian clock. Neurosci. Lett. 2010, 484:148-152.
38. Horvath G., Brubel R., Kovacs K., Reglodi D., Opper B., Ferencz A., Szakaly P., Laszlo E., Hau L., Kiss P., Tamas A., Racz B. Effects of PACAP on oxidative stress-induced cell death in primary rat kidney and human hepatocyte cell cultures. J. Mol. Neurosci. 2011, 43:67-75.
39. Huang W.T., Li C.J., Wu P.J., Chang Y.S., Lee T.L., Weng C.F. Expression and in vitro regulation of pituitary adenylate cyclase activating polypeptide (pacap38) and its type I receptor (pac1-r) in the gonads of tilapia (Oreochromis mossambicus). Reproduction 2009, 137:449-467.
40. Ishizuka O., Alm P., Larsson B., Matthiason A., Andersson K.E. Facilitatory effect of pituitary adenylate cyclase activating polypeptide on micturition in normal, conscious rat. Neuroscience 1995, 66:1009-1014.
41. Jobling, P. in press. Autonomic control of the urogenital tract. Auton. Neurosci., PMID: 20727839.
42. Khan, A.M., Li, M., Brant, E., Maderdrut, J.L., Majid, D.S.A., Simon, E.E., Batuman, V., in press. Renoprotection with pituitary adenylate cyclase activating polypeptide in cyclosporin A-induced nephrotoxicity. J. Invest. Med., PMID: 21383633.
43. Kemeny A., Reglodi D., Cseharovszky R., Hashimoto H., Baba A., Szolcsanyi J., Helyes Zs. Pituitary adenylate cyclase activating deficiency enhances oxazolone-induced allergic contact dermatitis in mice. J. Mol. Neurosci. 2010, 42:443-449.
44. LaBerge J., Malley S.E., Girard B., Corrow K., Vizzard M.A. Postnatal expression of corticotropin releasing factor (CRF) in rat urinary bladder. Auton. Neurosci. 2008, 141:83-93.
45. Lam H.C., Takahashi K., Ghatei M.A., Kanse S.M., Polak J.M., Bloom S.R. Binding sites of a novel neuropeptide pituitary adenylate cyclase activating polypeptide in the rat brain and lung. Eur. J. Biochem. 1990, 193:725-729.
46. Le S.V., Yamaguchi D.J., McArdle C.A., Tachiki K., Pisegna J.R., Germano P. PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells. Regul. Pept. 2002, 109:115-125.
47. Lee J., Park H.J., Choi H.S., Kwon H.B., Arimura A., Lee B.J., Choi W.S., Chun S.Y. Gonadotropin stimulation of pituitary adenylate cyclase activating polypeptide (PACAP) messenger ribonucleic acid in the rat ovary and the role of PACAP as a follicle survival factor. Endocrinology 1999, 140:818-826.
48. Lenti L., Domoki F., Kis D., Hegyi O., Toth G.K., Busija D.W., Bari F. Pituitary adenylate cyclase activating polypeptide induces pial arteriolar vasodilation through cyclooxigenase-dependent and independent mechanisms in newborn pigs. Brain Res. 2007, 1165:81-88.
49. Li M., Cortez S., Nakamachi T., Batuman V., Arimura A. Pituitary adenylate cyclase activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Cancer Res. 2006, 66:8796-8803.
50. Li M., Maderdrut J.L., Lertora J.J.L., Batuman V. Intravenous infusion of pituitary adenylate cyclase activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 2007, 28:1891-1895.
51. Li M., Hering-Smith K.S., Simon E.E., Batuman V. Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol. Dial. Transplant. 2008, 23:860-870.
52. Li M., Maderdrut J.L., Lertora J.J.L., Arimura A., Batuman V. Renoprotection by pituitary adenylate cyclase activating polypeptide in multiple myeloma and other kidney diseases. Regul. Pept. 2008, 145:24-32.
53. Li M., Balamuthusamy S., Khan A.M., Maderdrut J.L., Simon E.E., Batuman V. Pituitary adenylate cyclase activating polypeptide ameliorates cisplatin-induced acute kidney injury. Peptides 2010, 31:592-602.
54. Li M., Khan A.M., Maderdrut J.L., Simon E.E., Batuman V. The effect of PACAP38 on MyD88-mediated signal transduction in ischemia-/hypoxia-induced acute kidney injury. Am. J. Nephrol. 2010, 32:522-532.
55. Li M., Balamuthusamy S., Khan A.M., Maderdrut J.L., Simon E.E., Batuman V. Pituitary adenylate cyclase activating polypeptide prevents cisplatin-induced renal failure. J. Mol. Neurosci. 2011, 43:58-66.
56. -/- mice. J. Urol. 2010, 183:772-779.
57. Mester L., Kovacs K., Racz B., Solti I., Atlasz T., Szabadfi K., Tamas A., Reglodi D. Pitutary adenylate cyclase activating polypeptide is protective against oxidative stress in human retinal pigment epithelial cells. J. Mol. Neurosci. 2011, 43:35-43.
58. Mirabella N., Squillacioti C., Germano G., Varricchio E., Paino G. Pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactivity in the ureter of the duck. Cell Tissue Res. 2001, 305:341-349.
59. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M.D., Coy D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 1989, 164:567-574.
60. Mohammed H., Hannibal J., Fahrenkrug J., Santer R. Distribution and regional variation of pituitary adenylate cyclase activating polypeptide and other neuropeptides in the urinary bladder and ureter: effects of age. Urol. Res. 2002, 30:248-255.
61. Moller K., Zhang Y.Z., Hakanson R., Luts A., Sjolund B., Uddman R., Sundler F. Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 1993, 57:725-732.
62. Nakamachi T., Ohtaki H., Yofu S., Dohi K., Watanabe J., Mori H., Sato A., Hashimoto H., Shintani N., Baba A., Shioda S. Endogenous pituitary adenylate cyclase activating polypeptide is involved in suppression of edema in the ischemic brain. Acta Neurochir. Suppl. 2010, 106:43-46.
63. Nakamachi T., Farkas J., Watanabe J., Ohtaki H., Dohi K., Arata S., Shioda S. Role of PACAP in neural stem/progenitor cell and astrocyte- from neural development to neural repair. Curr. Pharm. Des. 2011, 17:973-984.
64. Nemetz N., Abad C., Lawson G., Nobuta H., Chhith S., Duong L., Tse G., Braun J., Waschek J.A. Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP. Int. J. Cancer 2008, 122:1803-1809.
65. Nilsson S.F. PACAP-27 and PACAP-38: vascular effects in the eye and some other tissues in the rabbit. Eur. J. Pharmacol. 1994, 253:17-25.
66. Ohtaki H., Nakamachi T., Dohi K., Shioda S. Role of PACAP in ischemic neural death. J. Mol. Neurosci. 2008, 36:16-25.
67. Ohtaki H., Satoh A., Nakamachi T., Yofu S., Dohi K., Mori H., Ohara K., Miyamoto K., Hashimoto H., Shintani N., Baba A., Matsunaga M., Shioda S. Regulation of oxidative stress by pituitary adenylate cyclase activating polypeptide (PACAP) mediated by PACAP receptor. J. Mol. Neurosci. 2010, 42:397-403.
68. Oka H., Jin L., Kulig E., Scheithauer B.W., Lloyd R.V. Pituitary adenylate cyclase activating polypeptide inhibits transforming growth factor-β1-induced apoptosis in a human pituitary adenoma cell line. Am. J. Pathol. 1999, 155:1893-1900.
69. Olsson C., Holmgren S. Distribution of PACAP (pituitary adenylate cyclase-activating polypeptide)-like and helospectin-like peptides in the teleost gut. Cell Tissue Res. 1994, 277:539-547.
70. Onoue S., Hanato J., Yamada S. Pituitary adenylate cyclase activating polypeptide attenuates streptozotocin-induced apoptotic death of RIN-m5F cells through regulation of Bcl-2 family protein mRNA expression. FEBS J. 2008, 275:5542-5551.
71. Peeters K., Gerets H.H., Princen K., Vandesande F. Molecular cloning and expression of a chicken pituitary adenylate cyclase activating polypeptide receptor. Mol. Brain Res. 1999, 71:244-255.
72. Pinhasov A., Nesher E., Gross M., Turgeman G., Kreinin A., Yadid G. The role of the PACAP signaling system in depression. Curr. Pharm. Des. 2011, 17:990-1001.
73. Racz B., Gasz B., Borsiczky B., Gallyas F., Tamas A., Jozsa R., Lubics A., Kiss P., Roth E., Ferencz A., Toth G., Hegyi O., Wittmann I., Lengvari I., Somogyvari-Vigh A., Reglodi D. Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis. Gen. Comp. Endocrinol. 2007, 153:115-123.
74. Racz B., Gasz B., Gallyas F., Kiss P., Tamás A., Jozsa R., Lubics A., Lengvari I., Toth G., Hegyi O., Roth E., Reglodi D. PKA-Bad-14-3-3 and Akt-Bad-14-3-3 signaling pathways are involved in the protective effects of PACAP against ischemia/reperfusion-induced cardiomyocyte apoptosis. Regul. Pept. 2008, 145:105-115.
75. Racz B., Reglodi D., Horvath G., Szigeti A., Balatonyi B., Roth E., Weber Gy., Alotti N., Toth G., Gasz B. Protective effect of PACAP against doxorubicin-induced cell death in cardiomyocyte culture. J. Mol. Neurosci. 2010, 42:419-427.
76. Radziszewski P., Ekblad E., Sundler F., Mattiason A. Distribution of neuropeptide-, tyrosine hydroxylase- and nitric oxide synthase containing nerve fibers in the external urethral sphincter of the rat. Scand. J. Urol. Nephrol. Suppl. 1996, 179:81-85.
77. Radziszewski P., Majewski M., Baranowski W., Czaplicki M., Bossowska A., Dobronski P., Borkowski A. Re-innervation pattern of the neovagina created from the bladder flap in patients with Mayer-Rokitanski-Kistner-Hauser syndrome: an immunohistochemical study. Gynecol. Endocrinol. 2009, 25:362-371.
78. Reglodi D., Kiss P., Lubics A., Tamas A. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr. Pharm. Des. 2011, 17:962-972.
79. Reglodi D., Somogyvari-Vigh A., Vigh S., Kozicz T., Arimura A. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 2000, 31:1411-1417.
80. Reubi J.C. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. NY Acad. Sci. 2000, 921:1-25.
81. Reubi J.C., Laderach U., Waser B., Gebbers J.O., Robberecht P., Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000, 60:3105-3112.
82. Riera M., Torras J., Cruzado J.M., Lloberas N., Liron J., Herrero I., Navarro M.A., Grinyo J.M. The enhancement of endogenous cAMP with pituitary adenylate cyclase activating polypeptide protects rat kidney against ischemia through the modulation of inflammatory response. Transplantation 2001, 72:1217-1223.
83. Roth E., Weber G., Kiss P., Horvath G., Toth G., Gasz B., Ferencz A., Gallyas F., Reglodi D., Racz B. Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. Ann. NY Acad. Sci. 2009, 1163:512-516.
84. Sakurai Y., Shintani N., Hayata A., Hashimoto H., Baba A. Trophic effect of PACAP on pancreatic islets: a mini-review. J. Mol. Neurosci. 2011, 43:3-7.
85. Sandor K., Kormos V., Botz B., Imreh A., Bolcskei K., Gaszner B., Markovics A., Szolcsanyi J., Shintani N., Hashimoto H., Baba A., Reglodi D., Helyes Zs. Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase activating polypeptide deficient mice. Neuropeptides 2010, 44:363-371.
86. Sano H., Miyata A., Horio T., Nichikimi T., Matsuo H., Kangawa K. The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor. Regul. Pept. 2002, 109:107-113.
87. Seaborn T., Masmoudi O., Fournier A., Vaudry H., Vaudry D. Protective effects of pituitary adenylate cyclase activating polypeptide (PACAP) against apoptosis. Curr. Pharm. Des. 2011, 17:204-214.
88. Senguil S., Li M., Batuman V. Myeloma kidney: toward its prevention- with new insights from in vitro and in vivo models of renal injury. J. Nephrol. 2009, 22:17-28.
89. Shioda S., Ohtaki H., Nakamachi T., Dohi K., Watanabe J., Nakajo S., Arata S., Kitamura S., Okuda H., Takenoya F., Kitamura Y. Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann. NY Acad. Sci. 2006, 1070:550-560.
90. Shivers B.D., Gorcs T.J., Gottschall P.E., Arimura A. Two high affinity binding sites for pituitary adenylate cyclase activating polypeptide have different tissue distibutions. Endocrinology 1991, 128:3055-3065.
91. Somogyvari-Vigh A., Reglodi D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr. Pharm. Des. 2004, 10:2861-2889.
92. Sreedharan S.P., Huang J.X., Cheung M.C., Goetzl E.J. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc. Natl. Acad. Sci. USA 1995, 92:2939-2943.
93. Szakaly P., Kiss P., Lubics A., Magyarlaki T., Tamas A., Racz B., Lengvari I., Toth G., Reglodi D. Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia-reperfusion. J. Mol. Neurosci. 2008, 36:89-96.
94. Szakaly P., Horvath G., Kiss P., Laszlo E., Farkas J., Furjes G., Nemeth J., Reglodi D. Changes in pituitary adenylate cyclase activating polypeptide following renal ischemia-reperfusion in rats. Transplant. Proc. 2010, 42:2283-2286.
95. Szakaly P., Laszlo E., Kovacs K., Racz B., Horvath G., Ferencz A., Lubics A., Kiss P., Tamas A., Brubel R., Opper B., Baba A., Hashimoto H., Farkas J., Matkovits A., Magyarlaki T., Helyes Zs., Reglodi D. Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury. Neuropeptides 2011, 45:113-121.
96. Tanida M., Shintani N., Morita Y., Tsukiyama N., Hatanaka M., Hashimoto H., Sawai H., Baba A., Nagai K. Regulation of autonomic nerve activities by central pituitary adenylate cyclase activating polypeptide. Regul. Pept. 2010, 161:73-80.
97. Uchida D., Arimura A., Somogyvari-Vigh A., Shioda S., Banks W.A. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res. 1996, 736:280-286.
98. Vaudry D., Hamelink C., Damadzic R., Eskay R.L., Gonzalez B., Eiden L.E. Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult. Peptides 2005, 26:2518-2524.
99. Vaudry D., Falluel-Morel A., Bourgault S., Basille M., Burel D., Wurtz O., Fournier A., Chow B.K., Hashimoto H., Galas L., Vaudry H. Pituitary adenylate cyclase activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 2009, 61:283-357.
100. Vizzard M.A. Up-regulation of pituitary adenylate cyclase activating polypeptide in urinary bladder pathways after chronic cystitis. J. Comp. Neurol. 2000, 420:335-348.
101. Vizzard M.A. Neurochemical plasticity and the role of neurotrophic factors in bladder reflex pathways after spinal cord injury. Prog. Brain Res. 2006, 152:97-115.
102. Waschek J.A. Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev. Neurosci. 2002, 24:14-23.
103. Watanabe J., Nakamachi T., Matsuno R., Hayashi D., Nakamura M., Kikuyama S., Nakajo S., Shioda S. Localization, characterization and function of pituitary adenylate cyclase-activating polypeptide during brain development. Peptides 2007, 28:1713-1719.
104. Wei Y., Mojsov S. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J. Neuroendocrinol. 1996, 8:811-817.
105. Werkstrom V., Persson K., Andersson K.E. NANC transmitters in the female pig urethra-localization and modulation of release via alpha2-adrenoceptors and potassium channels. Br. J. Pharmacol. 1997, 121:1605-1612.
106. Yoshiyama M., de Groat W.C. The role of vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide in the neural pathways controlling the lower urinary tract. J. Mol. Neurosci. 2008, 36:227-240.
107. Yoshiyama M., de Groat W.C. Effects of intrathecal administration of pituitary adenylate cyclase activating polypeptide on lower urinary tract functions in rats with intact or transected spinal cords. Exp. Neurol. 2008, 211:449-455.
108. Zvarova K., Dunleavy J.D., Vizzard M.A. Changes in pituitary adenylate cyclase activating polypeptide expression in urinary bladder pathways after spinal cord injury. Exp. Neurol. 2005, 192:46-59.